Omega-3 fatty acids are one of the few supplements where the evidence base is genuinely strong — not for everything they are marketed for, but for specific, well-defined clinical applications. The problem is that most patients are either taking too little to achieve a therapeutic effect, taking the wrong ratio of EPA to DHA for their condition, or taking a product that has already gone rancid on the shelf.
Here is what the research actually says about dosing omega-3 by condition, and what I use in clinical practice.
At a Glance
| Property | Detail |
|---|---|
| Evidence Level | Strong (cardiovascular risk reduction, depression); Moderate (cognitive function, neuroinflammation); Emerging (autoimmune modulation) |
| Key Compounds | EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) |
| Primary Mechanisms | Anti-inflammatory (EPA via resolvin/protectin pathways), structural (DHA in neuronal membranes), triglyceride reduction |
| Testing | Omega-3 index (target 8-12%) |
| Quality Standard | IFOS 5-star certified, triglyceride form, third-party tested for oxidation and heavy metals |
EPA vs DHA: They Are Not the Same
This is where most patients — and many clinicians — get it wrong. EPA and DHA are both long-chain omega-3 polyunsaturated fatty acids, but they have different biological roles, different tissue distributions, and different clinical evidence profiles.
EPA (Eicosapentaenoic Acid)
EPA is primarily an anti-inflammatory mediator. It competes with arachidonic acid (an omega-6 fatty acid) for incorporation into cell membranes and for access to the cyclooxygenase and lipoxygenase enzyme pathways. When EPA wins that competition, the downstream products are anti-inflammatory resolvins and protectins rather than pro-inflammatory prostaglandins and leukotrienes.
Where EPA shines:
- Depression: The strongest evidence for omega-3 in depression comes from EPA-predominant formulations. A meta-analysis by Liao et al. (2019) found that supplements with EPA at 60% or more of total omega-3 content showed significant antidepressant effects, while DHA-predominant formulations did not.
- Triglyceride reduction: Icosapent ethyl (Vascepa), a purified EPA ethyl ester at 4g daily, reduced cardiovascular events by 25% in the REDUCE-IT trial — a landmark RCT with over 8,000 patients.
- Systemic inflammation: EPA-derived specialized pro-resolving mediators (SPMs) actively resolve inflammation rather than merely suppressing it. This is a critical distinction.
DHA (Docosahexaenoic Acid)
DHA is a structural fatty acid. It constitutes approximately 40% of polyunsaturated fatty acids in the brain and 60% in the retina. It is literally a building block of neuronal membranes, where it modulates membrane fluidity, receptor function, and signal transduction.
Where DHA shines:
- Brain development: DHA is critical during pregnancy and early childhood. Maternal DHA supplementation is associated with improved cognitive and visual development in offspring. This evidence is strong.
- Cognitive function in aging: DHA supplementation shows the most consistent benefit for cognitive maintenance in older adults, particularly those with low baseline DHA status.
- Retinal health: DHA is the dominant omega-3 in the retina. The AREDS2 trial found that omega-3 supplementation did not reduce progression of age-related macular degeneration in the overall population, but subgroup analyses suggest benefit in those with low baseline intake.
The Clinical Implication
When a patient presents with depression and systemic inflammation, I prioritize EPA. When a patient presents with cognitive decline, neurodegeneration, or is pregnant, I prioritize DHA. When a patient presents with both — which is common in the chronic disease populations I treat — I use a combined formulation but adjust the ratio based on the primary clinical target.
Therapeutic Dosing vs Maintenance Dosing
The dose on a standard fish oil bottle — typically 1000mg of fish oil containing 300mg of combined EPA/DHA — is a maintenance dose at best. For therapeutic applications, the evidence points to substantially higher doses.
Dosing by Condition
| Condition | EPA | DHA | Combined Target | Evidence Level |
|---|---|---|---|---|
| Cardiovascular risk reduction | 2-4g EPA | — | 2-4g EPA (Vascepa model) | Strong (REDUCE-IT) |
| Depression (adjunct) | 1-2g EPA | 0-500mg DHA | 1-2.5g (EPA predominant) | Strong (meta-analyses) |
| Cognitive support / neurodegeneration | 500mg-1g EPA | 1-2g DHA | 1.5-3g (DHA predominant) | Moderate |
| Neuroinflammation (Lyme, post-COVID) | 2-3g EPA | 1g DHA | 3-4g combined | Moderate (clinical observation) |
| Pregnancy | 200-500mg EPA | 300-600mg DHA | 500-1000mg combined | Strong (WHO recommends 200mg DHA minimum) |
| General maintenance | 500mg EPA | 500mg DHA | 1g combined | Moderate |
| Triglyceride reduction | 4g EPA (prescription icosapent ethyl) | — | 4g EPA | Strong (REDUCE-IT) |
In my clinical practice, most patients with chronic inflammatory conditions are on 3-4 grams of combined EPA/DHA daily. This is not a casual supplement recommendation — it is a therapeutic intervention based on their clinical picture and confirmed by omega-3 index testing.
The Omega-3 Index: Test, Don’t Guess
The omega-3 index measures the percentage of EPA and DHA in red blood cell membranes. It reflects your actual omega-3 status over the preceding 2-3 months — similar to how HbA1c reflects blood sugar.
| Omega-3 Index | Interpretation |
|---|---|
| Below 4% | Deficient — associated with highest cardiovascular risk |
| 4-8% | Suboptimal — most Western populations fall here |
| 8-12% | Optimal — associated with lowest cardiovascular risk and best clinical outcomes |
| Above 12% | High — no clear additional benefit; monitoring warranted |
Harris and Von Schacky (2004) proposed the omega-3 index as a cardiovascular risk factor, with an index below 4% associated with a 10-fold higher risk of sudden cardiac death compared to an index above 8%. Subsequent epidemiological data has supported this relationship.
What I tell my patients: taking omega-3 supplements without testing your omega-3 index is like taking blood pressure medication without measuring your blood pressure. You need to know where you are starting and whether the dose is working. I test at baseline and recheck at 3 months.
The response to supplementation is highly individual. Absorption varies based on formulation (triglyceride vs ethyl ester), whether taken with a fat-containing meal, gut health, and genetic factors affecting fatty acid metabolism. Some patients need 2 grams daily to reach an index of 8%. Others need 4 grams. Testing eliminates the guesswork.
Fish Oil vs Algal Oil
Fish oil is the traditional source and provides both EPA and DHA. Quality varies enormously — from pharmaceutical-grade concentrates to rancid, low-potency products with undisclosed heavy metal content.
Algal oil is derived from microalgae — the organisms that fish themselves obtain omega-3 from. It is the original source. Algal oil has historically been DHA-predominant, but newer products provide meaningful EPA content as well.
For my vegetarian and vegan patients, algal oil is the obvious choice. For patients concerned about environmental sustainability or heavy metal exposure, algal oil has advantages. The bioavailability of well-formulated algal oil is comparable to fish oil.
For most patients, I recommend fish oil concentrates simply because achieving therapeutic doses of EPA (2-3 grams) is more practical with concentrated fish oil products. This may shift as algal oil technology continues to improve.
Quality Markers: What to Look For
Supplements are real science — but the quality in this industry is a serious problem. Here is what distinguishes a therapeutic-grade omega-3 product from a worthless one:
Non-Negotiable Quality Criteria
-
Third-party testing. IFOS (International Fish Oil Standards) 5-star certification is the gold standard. It tests for potency, purity (heavy metals, PCBs, dioxins), and freshness (oxidation markers).
-
Triglyceride form. Omega-3 supplements come in two forms: triglyceride (TG) and ethyl ester (EE). TG form has 50-70% better bioavailability than EE form based on published comparison studies. The exception is prescription icosapent ethyl, which is an EE form studied specifically at 4g doses.
-
Oxidation values. Rancid fish oil is worse than no fish oil — oxidized lipids are pro-inflammatory. Check for TOTOX (total oxidation) values below 26 (GOED standard). If the product smells strongly fishy, it is likely oxidized.
-
EPA and DHA content per serving. Read the label carefully. “1000mg fish oil” is not “1000mg omega-3.” Look for the actual EPA and DHA milligrams. Quality concentrates provide 500-900mg of combined EPA/DHA per capsule.
-
Heavy metal testing. Mercury, lead, cadmium, and arsenic should be below detection limits in a quality product. Third-party certificates of analysis should be available.
Red Flags
- No third-party testing certification
- Only lists “total omega-3” without specifying EPA and DHA separately
- Extremely low price per gram of EPA/DHA (usually indicates poor concentration or ethyl ester form)
- Strong fishy taste or smell (oxidation)
- Added “proprietary blends” of other ingredients
Practical Application
How to Take Omega-3
With food. Always take omega-3 supplements with a meal containing fat. Lipase activity is required for absorption, and bile secretion triggered by dietary fat improves absorption of both TG and EE forms by 3-5 fold.
Split dosing. For therapeutic doses above 2 grams, split into 2-3 doses per day to improve absorption and reduce the GI side effects (fishy burps, nausea) that some patients experience.
Timing. No specific time of day matters. Consistency matters more than timing.
Duration. Omega-3 is not a short-term intervention. Cell membrane composition changes over weeks to months. I recommend a minimum of 3 months at therapeutic doses before assessing clinical response, confirmed by omega-3 index testing.
When to Use Caution
- Anticoagulant therapy. Omega-3 at doses above 3 grams has a mild antiplatelet effect. It does not replace anticoagulants and the interaction risk is low, but monitoring is appropriate in patients on warfarin or DOACs.
- Scheduled surgery. Some surgeons recommend stopping high-dose omega-3 7-10 days before elective surgery due to theoretical bleeding risk. The clinical significance is debated, but I advise patients to discuss this with their surgical team.
- Fish allergy. Highly purified fish oil concentrates generally do not contain allergenic fish proteins, but patients with severe fish allergy should consider algal oil or discuss with their allergist.
- Pregnancy. DHA supplementation is recommended during pregnancy. However, certain fish oil products may contain vitamin A (from liver oil) — which should be limited in pregnancy. Pure EPA/DHA concentrates are preferred.
What I Use in Practice
In my clinical experience treating patients with chronic Lyme disease, post-COVID syndrome, and complex chronic illness, omega-3 is one of the foundational supplements I recommend for nearly every patient. The reasons are straightforward:
- The anti-inflammatory evidence is strong and directly relevant to the conditions I treat
- Most patients arrive with omega-3 indices below 6% — they are demonstrably deficient
- The safety profile at therapeutic doses is excellent
- It is one of the few supplements where I can objectively measure whether the intervention is working
I typically start patients on 3 grams of combined EPA/DHA daily (EPA-predominant for inflammatory conditions, balanced for cognitive support), test their omega-3 index at baseline and 3 months, and adjust the dose to achieve an index of 8-12%.
This is not a magic supplement. It is basic biochemistry — providing the substrate for anti-inflammatory resolution pathways that are depleted in chronic disease. When combined with NAC for glutathione support, targeted neuromodulation for brain fog, and treatment of the underlying condition, it is a meaningful contributor to recovery.
The Bottom Line
EPA and DHA have different roles: EPA for inflammation, DHA for brain structure. Therapeutic doses are 2-4 grams combined — far higher than typical supplement labels suggest. Test your omega-3 index to eliminate guesswork. Buy quality products (IFOS-certified, triglyceride form, third-party tested). Take with food.
The evidence is strong for cardiovascular risk reduction and depression, moderate for cognitive support and neuroinflammation. This is one of the supplements where the science genuinely supports the use — provided you take the right dose of the right product and actually measure whether it is working.
References
-
Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9(1):190. PMID: 31383846.
-
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11-22. PMID: 30415628.
-
Harris WS, Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39(1):212-220. PMID: 15208005.
-
Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015;7:52. PMID: 25954194.
-
Schuchardt JP, Hahn A. Bioavailability of long-chain omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2013;89(1):1-8. PMID: 23676322.
Disclaimer: This article is for educational purposes. Omega-3 supplementation at therapeutic doses should be discussed with your physician, particularly if you are on anticoagulant therapy, pregnant, or scheduled for surgery. This content does not constitute individualized medical advice.
